Visualizing & Targeting Cancer

Targeting and Treating Cancer

Compassionate. Determined. Infinitely resourceful. Our mission as an oncology company is to develop innovative products that benefit cancer patients and their families. Learn More

Visualizing Prostate Cancer

Visualizing Prostate Cancer

Our development stage imaging agent visualizes prostate cancer, turning watchful waiting into active surveillance. Learn More

He is our mission

He is your

He is our mission.

Prostate cancer is the second most common form of cancer affecting men in the United States: An estimated one in six will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that approximately 240,000 new cases of prostate cancer will be diagnosed and about 30,000 men will die of the disease this year. Approximately 2 million men in the U.S. currently count themselves among prostate cancer survivors.

Learn More »

About Progenics

Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics’ pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA®, 1095, and PSMA TTC), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis technology. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc. Learn more

Product Pipeline


Our pipeline includes candidates in all stages of development. See All